-transparent.png){kind=logo}
14 patients with classical or definite rheumatoid arthritis and a low number of E-rosette forming cells were given single doses of 5 mg and 50 mg of thymopoietin intravenously. Thymopoietin pentapeptide produced a dose-related sustained increase in E-rosette forming lymphocytes as shown by the decrease of thymopoietin dependent rosetting ratio. A single dose of 50 mg restored the number of E-rosette forming cells to normal after 12 h and this effect lasted 60 to 7 days. With the administration of 5 E-rosette forming cells markedly increased after 12 h and returned to the pretreatment level on the 2nd day. These immunokinetic data clarify some aspects of the clinical pharmacology of thymopoietin pentapeptide and must be considered for a rational schedule of treatment with the drug.
T Di Perri, and
F Laghi Pasini, and
A Auteri
November 1983,
Journal of the American Academy of Dermatology,
T Di Perri, and
F Laghi Pasini, and
A Auteri
March 1983,
Lancet (London, England),
T Di Perri, and
F Laghi Pasini, and
A Auteri
March 1984,
Deutsche medizinische Wochenschrift (1946),
T Di Perri, and
F Laghi Pasini, and
A Auteri
January 1980,
Lancet (London, England),
T Di Perri, and
F Laghi Pasini, and
A Auteri
June 1979,
Science (New York, N.Y.),
T Di Perri, and
F Laghi Pasini, and
A Auteri
January 1984,
Dermatologische Monatschrift,
T Di Perri, and
F Laghi Pasini, and
A Auteri
September 1981,
Journal of clinical & laboratory immunology,
T Di Perri, and
F Laghi Pasini, and
A Auteri
January 1983,
Birth defects original article series,
T Di Perri, and
F Laghi Pasini, and
A Auteri
October 1982,
Annals of the rheumatic diseases,
T Di Perri, and
F Laghi Pasini, and
A Auteri
January 1984,
International journal of peptide and protein research,
